5th Circ. Revives Unfair Competition Fight Over Arthritis Drug

By Dorothy Atkins · April 11, 2025, 5:28 PM EDT

The Fifth Circuit has revived Zyla Life Sciences LLC's lawsuit seeking to block Texas rival Wells Pharma from selling rheumatoid arthritis drug suppositories that aren't U.S. Food and Drug Administration-approved, rejecting...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Zyla Life Sciences v. Wells Pharma

Case Number

Court

Appellate - 5th Circuit

Nature of Suit

4380 Other Personal Property Damage

Date Filed

October 31, 2023

Recent Articles By Dorothy

April 02, 2025
Congress Demands VA Update Health Record System Costs
April 01, 2025
IBM And J&J Beat 'Speculative' Data Breach Suit, For Now
March 31, 2025
Buyer Class Of Surgical Robots Is Certified In Antitrust Fight
March 31, 2025
DocGo Can't Nix Investor Suit Over 'Indisputably False' Claims
March 18, 2025
Full 9th Circ. Mulls Reviving Workers' LA Schools Vax Fight
March 05, 2025
BCBS Hit With New Antitrust Suits By $2.8B Deal Opt-Outs
March 05, 2025
Nationwide Block Of Trump Trans Healthcare Orders Extended
March 04, 2025
Calif. PBM Opioid Suit Belongs In Federal Court, 9th Circ. Told
February 24, 2025
Elizabeth Holmes Loses 9th Circ. Appeal Over Theranos Fraud
February 14, 2025
Judge Upholds Pay-For-Delay Ban Law, But Only In Calif.